, /PRNewswire/ -- , a full-stack spatial biology company, today announced it has raised in additional funding co-led by existing investors and Lions Capital LLC, and participation from , , , and as well as existing investors. , Managing Partner at Lions Capital Partners LLC, will join the company's Board, and , Chief Scientific Officer of Germin8 Ventures, will join as a board observer. The fresh capital closely follows a and brings Kanvas's total funding to .
The funding will be used to further develop the company's spatial biology platform and advance two novel therapeutics in its Immuno-oncology Program, — KAN-001 to an Investigational New Drug (IND) filing in 2025. The Kanvas platform is unique in its ability to spatially map gene expression and cellular function across all kingdoms of life. Its unprecedented capability to illuminate host-microbiome interactions marks a significant advancement in understanding diseases related to the microbiomes, finally unlocking the promise of microbiome-based therapies.
The platform provides not only a path to breakthroughs in drug development, but also clinical diagnostics, agriculture and food safety. Kanvas Bioscience's spatial biology platform provides the unique ability to map host-microbiome interactions and leverage the resulting data to design live biotherapeutic products (LBPs), which can be used to create novel microbiome-based therapies that optimize the microbiome – a critical factor in human health. KAN-001, the compan.
